Paunovic 2010.

Methods	Design: randomised, double‐blind, 2 parallel‐group study Location and number of centres: not reported
Participants	Number screened: not reported Number randomised: 420 Number completed: not reported Age: 7 to 12 years Gender: not reported Asthma severity: FEV1 50‐90% of predicted Inclusion/exclusion criteria: not described
Interventions	1. Ciclesonide once daily (160 µg/day) 2. Fluticasone twice daily (176 µg/day) Delivery: not reported Inhalation technique: not reported Treatment period: 12 weeks (following 2 to 4 weeks baseline period rescue medication only) Allowed asthma medication: not reported
Outcomes	Forced expiratory volume in 1 second (FEV1) (mL), peak expiratory flow (PEF) (L/minute), asthma symptom scores, rescue medication use, asthma exacerbation
Notes	Incomplete data since this study was only published as an abstract
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding (performance bias and detection bias) Outcomes 1, 3, 4, 5	Unclear risk	Not described
Blinding (performance bias and detection bias) Other outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) Outcomes 1, 3, 4, 5	Unclear risk	Not described
Incomplete outcome data (attrition bias) Other outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	Unclear risk	Not enough information
Other bias	Unclear risk	Not enough information